It may be worth mentioning that about 60% of initially HER2-postive patients who did not received adjuvant trastuzumab had been diagnosed prior to the year 2005, that is, prior to the AIFA approval relatively to the use of adjuvant trastuzumab in HER2-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.